ABSTRACT
The protein level of muscle-specific human NogoA is abnormally upregulated in amyotrophic lateral sclerosis (ALS) mice and patients. On the other hand, while the presence of miR-206 in muscle cells delays onset and death in ALS, the relationship between these two phenomena remains unclear. Mammalian NogoA protein, also known as Reticulon 4a (Rtn4a), plays an important role in inhibiting the outgrowth of motor neurons. Our group previously identified zebrafish rtn4al as the target gene of miR-206 and found that knockdown of miR-206 increases rtn4al mRNA and Rtn4al protein in zebrafish embryos. It can be concluded from these results that neurite outgrowth of motor neurons is inhibited by Rtn4a1, which is entirely consistent with overexpression of either human NogoA or zebrafish homolog Rtn4al. Since an animal model able to express NogoA/rtn4al at the mature stage is unavailable, we generated a zebrafish transgenic line, Tg(Zα:TetON-Rtn4al), which conditionally and specifically overexpresses Rtn4al in the muscle tissue. After doxycycline induction, adult zebrafish displayed denervation at neuromuscular junction during the first week, then muscle disintegration and split myofibers during the third week, and, finally, significant weight loss in the sixth week. These results suggest that this zebrafish transgenic line, representing the inducible overexpression of Rtn4a1 in muscle, may provide an alternative animal model with which to study ALS because it exhibits ALS-like phenotype.
Subject(s)
Amyotrophic Lateral Sclerosis/genetics , Disease Models, Animal , Motor Neurons/metabolism , Myelin Proteins/genetics , Neuromuscular Junction/metabolism , Zebrafish Proteins/genetics , Zebrafish/genetics , Amyotrophic Lateral Sclerosis/metabolism , Amyotrophic Lateral Sclerosis/physiopathology , Animals , Animals, Genetically Modified , Doxycycline/pharmacology , Embryo, Nonmammalian , Gene Expression Regulation/drug effects , Humans , MicroRNAs/genetics , MicroRNAs/metabolism , Morpholinos/genetics , Morpholinos/metabolism , Motor Neurons/pathology , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Muscle, Skeletal/physiopathology , Myelin Proteins/agonists , Myelin Proteins/antagonists & inhibitors , Myelin Proteins/metabolism , Neuromuscular Junction/pathology , Neuromuscular Junction/physiopathology , Nogo Proteins/agonists , Nogo Proteins/genetics , Nogo Proteins/metabolism , Oligonucleotides, Antisense/genetics , Oligonucleotides, Antisense/metabolism , Phenotype , Plasmids/chemistry , Plasmids/metabolism , Zebrafish/embryology , Zebrafish/metabolism , Zebrafish Proteins/agonists , Zebrafish Proteins/antagonists & inhibitors , Zebrafish Proteins/metabolismABSTRACT
Stroke induces a biphasic effect on the peripheral immune response that involves early activation of peripheral leukocytes followed by severe immunosuppression and atrophy of the spleen. Peripheral immune cells, including T lymphocytes, migrate to the brain and exacerbate the developing infarct. Recombinant T-cell receptor (TCR) Ligand (RTL)551 is designed as a partial TCR agonist for myelin oligodendrocyte glycoprotein (MOG)-reactive T cells and has demonstrated the capacity to limit infarct volume and inflammation in brain when administered to mice undergoing middle cerebral artery occlusion (MCAO). The goal of this study was to determine if RTL551 could retain protection when given within the therapeutically relevant 4 h time window currently in clinical practice for stroke patients. RTL551 was administered subcutaneously 4 h after MCAO, with repeated doses every 24 h until the time of euthanasia. Cell numbers were assessed in the brain, blood, spleen and lymph nodes and infarct size was measured after 24 and 96 h reperfusion. RTL551 reduced infarct size in both cortex and striatum at 24 h and in cortex at 96 h after MCAO and inhibited the accumulation of inflammatory cells in brain at both time points. At 24 h post-MCAO, RTL551 reduced the frequency of the activation marker, CD44, on T-cells in blood and in the ischemic hemisphere. Moreover, RTL551 reduced expression of the chemokine receptors, CCR5 in lymph nodes and spleen, and CCR7 in the blood and lymph nodes. These data demonstrate effective treatment of experimental stroke with RTL551 within a therapeutically relevant 4 h time window through immune regulation of myelin-reactive inflammatory T-cells.
Subject(s)
Brain , Infarction, Middle Cerebral Artery , Myelin Proteins , Receptors, Antigen, T-Cell/agonists , Recombinant Fusion Proteins/therapeutic use , Animals , Blood/immunology , Blood/metabolism , Brain/immunology , Brain/metabolism , Disease Models, Animal , Humans , Hyaluronan Receptors/immunology , Hyaluronan Receptors/metabolism , Infarction, Middle Cerebral Artery/pathology , Infarction, Middle Cerebral Artery/therapy , Lymph Nodes/immunology , Lymph Nodes/metabolism , Male , Mice , Mice, Inbred C57BL , Myelin Proteins/agonists , Myelin Proteins/immunology , Myelin-Oligodendrocyte Glycoprotein , Receptors, Antigen, T-Cell/immunology , Receptors, CCR5/immunology , Receptors, CCR5/metabolism , Receptors, CCR7/immunology , Receptors, CCR7/metabolism , Spleen/immunology , Spleen/metabolism , T-Lymphocytes/immunology , Time Factors , Treatment OutcomeABSTRACT
The interaction between Nogo-66 and its receptor NgR represents a promising target for designing drugs to treat CNS axonal injury which often leads to permanent disability. Unfortunately, the isolated Nogo-66 is highly insoluble while its truncated form Nogo-40 is soluble but unstructured, thus retarding further characterization and application. Here, we rationally design another soluble form Nogo-54. CD and NMR characterization reveals that Nogo-54 is structured, and importantly, is able to mimic Nogo-66 in inhibiting neurite outgrowth. Strikingly, mutating its C-terminal four residues (Lys50, Glu51, Arg53, and Arg54) leads to a mutant Nogo-54m which has no dramatic structural change but whose inhibitory activity is completely abolished. This strongly suggests that the four charged residues contribute significantly to the inhibitory action of Nogo-66. Furthermore, our study also provides a soluble and structured mimic as well as a possible antagonist for Nogo-66 which may hold promising potential for various medical applications.
Subject(s)
Myelin Proteins/chemistry , Myelin Proteins/pharmacology , Neurites/drug effects , Amino Acid Sequence , Central Nervous System/drug effects , Central Nervous System/physiology , Circular Dichroism , Drug Design , GPI-Linked Proteins , Humans , Mutation , Myelin Proteins/agonists , Myelin Proteins/antagonists & inhibitors , Myelin Proteins/genetics , Neurites/physiology , Nogo Proteins , Nogo Receptor 1 , Nuclear Magnetic Resonance, Biomolecular , Protein Conformation , Receptors, Cell Surface/agonists , Receptors, Cell Surface/antagonists & inhibitors , Solubility , Structure-Activity RelationshipABSTRACT
Nogo is a myelin-derived protein that limits axonal regeneration after CNS injury. A short hydrophilic Nogo-66 loop between two hydrophobic domains of Nogo binds to a Nogo-66 receptor (NgR) to inhibit axonal outgrowth. Inhibition of axon outgrowth and cell spreading by a second Nogo domain, termed Amino-Nogo-A, is thought to be mediated by a distinct receptor complex. Here, we define a novel Nogo-A-specific domain in Amino-Nogo that binds to NgR with nanomolar affinity. This second domain of 24 amino acids does not alter cell spreading or axonal outgrowth. Fusion of the two NgR-binding Nogo-A domains creates a ligand with substantially enhanced affinity for NgR and converts a NgR antagonist peptide to an agonist. Thus, NgR activation by Nogo-A involves multiple sites of interaction between Nogo-A and NgR.